ARRS 2022 Abstracts


E2060. Liver Fibrosis in Asian Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
  1. Heon-Ju Kwon; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
  2. Won Sohn; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
  3. Yong Kyun Cho; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
This study aimed to evaluate risk factors associated with liver fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD).

Materials and Methods:
A cross-sectional study of 967 Korean patients with MAFLD involved a cohort from a health screening program during the years 2015–2018. The patients were classified into four MAFLD subgroups: group 1 (overweight), group 2 (obese), group 3 (lean/normal weight with metabolic abnormalities), and group 4 (diabetes). Liver fibrosis was assessed based on liver stiffness measurement (LSM) value using 2D real-time magnetic resonance elastography. We investigated differences in liver fibrosis according to MAFLD subgroup classification and determined the risk factors for significant fibrosis.

The mean age was 50.8 years, and 869 (90%) patients were male. The mean value of LSM in magnetic resonance elastography was 2.48 ± 0.47 kPa. Significant fibrosis (LSM = 2.97 kPa) was observed in 66 (6.8%) of 967 patients. The proportion of significant fibrosis in MAFLD group 1, group 2, group 3, and group 4 was 1.3%, 5.5%, 6.4%, and 18.9%, respectively (p < .001). Multivariable analysis indicated that the risk factors for significant fibrosis were: serum ferritin = 300 ng/mL (odds ratio [OR], 1.96; 95% confidence interval [CI], 1.10–3.49; p = .023), fibrosis-4 = 1.3 (OR, 2.97; 95% CI, 1.68–5.24; p < .001), homeostatic model assessment of insulin resistance = 2.0 (OR, 2.60; 95% CI, 1.25–5.43; p = .011), metabolic syndrome (OR, 2.53; 95% CI, 1.31–4.88; p = .006), and MAFLD group 4 (OR, 6.93; 95% CI, 1.96–24.51; p = .003); however, the etiology of liver disease was not statistically associated with liver fibrosis.

Liver fibrosis in patients with MAFLD varies according to subgroup classification based on diabetes, body mass index, and metabolic risk factors.